Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats

Abstract

Insulin resistance increases renal oxidant production by upregulating NADPH oxidase 4 (Nox4) expression contributing to oxidative damage and ultimately albuminuria. Inhibition of the renin-angiotensin system (RAS) and activation of glucagon-like peptide-1 (GLP-1) receptor signalling may reverse this effect. However, whether angiotensin receptor type 1 (AT1) blockade and GLP-1 receptor activation improve oxidative damage and albuminuria through different mechanisms is not known. Using insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rats, we tested the hypothesis that simultaneous blockade of AT1 and activation of GLP-1r additively decrease oxidative damage and urinary albumin excretion (U alb V) in the following groups:(a) untreated, lean LETO (n = 7), (b) untreated, obese OLETF (n = 9), (c) OLETF + angiotensin receptor blocker (ARB; 10 mg olmesartan/kg/d; n = 9), (d) OLETF + GLP-1 mimetic (EXE; 10 µg exenatide/kg/d; n = 7) and (e) OLETF + ARB +exenatide (Combo; n = 6). Mean kidney Nox4 protein expression and nitrotyrosine (NT) levels were 30% and 46% greater, respectively, in OLETF compared with LETO. Conversely, Nox4 protein expression and NT were reduced to LETO levels in ARB and EXE, and Combo reduced Nox4, NT and 4-hydroxy-2-nonenal levels by 21%, 27% and 27%, respectively.At baseline, U alb V was nearly double in OLETF compared with LETO and increased to nearly 10-fold greater levels by the end of the study. Whereas ARB (45%) and EXE (55%) individually reduced U alb V, the combination completely ameliorated the albuminuria. Collectively, these data suggest that AT1 blockade and GLP-1 receptor activation reduce renal oxidative damage similarly during insulin resistance, whereas targeting both signalling pathways provides added benefit in restoring and/or further ameliorating albuminuria in a model of diet-induced obesity. K E Y W O R D Schronic kidney disease, diabetes, obesity, oxidative stress, renin-angiotensin system | 423 RODRIGUEZ Et al.

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms

“…Recombinant human GLP-1 inhibits protein kinase C (PKC)b, but increases protein kinase A (PKA), which reduces oxidative stress in both glomeruli and tubules (Yin et al, 2019). Consistent with this observation, the combination of olmesartan and exenatide has been shown to attenuate the renal NADPH oxidase 4 (Nox4) expression in insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rats (Rodriguez et al, 2020). Hendarto et.…”

Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System

“…As two major metabolic signals regulating glycolipid metabolism, both GLP-1 and the RAS target islet and insulin within peripheral target organs (e.g., liver, skeletal muscle, and adipose tissue) through common or cross-reactive pathways (Leung and de Gasparo, 2009;Rodriguez et al, 2019). In addition, GLP-1-based drugs function as a new class of hypoglycemic drugs, and RAS inhibitors act as a classical class of anti-hypertensive drugs, which have also been confirmed to have anti-diabetic effects.…”

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

“…Olmesartan, exenatide and combined therapy reduced NT excretion to a similar extent (25, 22 and 27%, respectively) and combined treatment reduced urinary 4-HNE by 27%. These effects were parallel with a significant reduction of albuminuria in obese insulin-resistant drugs (by 45 and 55% in olmesartan and exenatide groups, respectively), and albuminuria was fully normalized when combined treatment was applied [ 94 ].…”